33 Poster Discussion - XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile. - Hsu, J.; Chong, C.; Goon, L.; Balayan, J.; Wu, S.; Johnson, E.; Lorenzana, G.; Bannen, L.; Nguyen, L.; Scheffold, C.; Lamb, P.; Xu, W.; et al. (European Journal of Cancer, 2020)